Head to Head Review: CollPlant Biotechnologies (NASDAQ:CLGN) vs. Werewolf Therapeutics (NASDAQ:HOWL)

Werewolf Therapeutics (NASDAQ:HOWL) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Werewolf Therapeutics and CollPlant Biotechnologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1	3	2	1	2.43
CollPlant Biotechnologies	1	1	0	0	1.50

Werewolf Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 308.33%. CollPlant Biotechnologies has a consensus price target of $120.00, suggesting a potential upside of 3,318.80%. Given CollPlant Biotechnologies’ higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Werewolf Therapeutics.

Institutional and Insider Ownership

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Werewolf Therapeutics and CollPlant Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%

Volatility and Risk

Werewolf Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Earnings and Valuation

This table compares Werewolf Therapeutics and CollPlant Biotechnologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88 million	25.32	-$60.82 million	($0.76)	-1.29
CollPlant Biotechnologies	$2.37 million	2.80	-$11.49 million	($13.59)	-0.26

CollPlant Biotechnologies has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Summary

Werewolf Therapeutics beats CollPlant Biotechnologies on 10 of the 15 factors compared between the two stocks.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.